BPR1K871是一种高效选择性的 FLT3/AURKA 双重抑制剂，对 FLT3 和 AURKA 作用的 IC50 值分别为 19 nM 和 22 nM。可作为抗癌治疗临床前开发的候选药物。
货号:ajcx13768
CAS:2443767-35-7
分子式:C25H28ClN7O2S
分子量：526.05
溶解度:DMSO: 125 mg/mL (237.62 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1]. IC50: 19 nM (FLT3), 22 nM (AURKA)[1]

BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM[1].

BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors[1].

[1]. Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239-86256.